StockMacro
Company, fund or insider

Help

Menu

Cardiff Oncology

$0.85 -56% in 6 monthsMarket cap $66.3M

CRDF on XNAS, Health Care, Cardiff Oncology, Inc., job postings

Measures activity, not value. Not investment advice.

Short interest reached 16% of shares as institutional holders fell 25% and shares lost 56% in a year.

  • BadNet loss of $37.6M over 12 months against $33.8M of cash

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
31
Website
cardiffoncology.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 13 May 2027 (an estimate: a year ago it reported on 14 May 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $171K, net loss $8.9M.
Quarter to 31 Dec 2021: revenue $133K, net income -$9.4MQuarter to 31 Dec 2021: revenue $133K, net income -$9.4MQuarter to 31 Mar 2022: revenue $74K, net income -$11.0MQuarter to 31 Mar 2022: revenue $74K, net income -$11.0MQuarter to 30 Jun 2022: revenue $91K, net income -$10.4MQuarter to 30 Jun 2022: revenue $91K, net income -$10.4MQuarter to 30 Sep 2022: revenue $93K, net income -$8.6MQuarter to 30 Sep 2022: revenue $93K, net income -$8.6MQuarter to 31 Dec 2022: revenue $128K, net income -$8.7MQuarter to 31 Dec 2022: revenue $128K, net income -$8.7MQuarter to 31 Mar 2023: revenue $83K, net income -$11.2MQuarter to 31 Mar 2023: revenue $83K, net income -$11.2MQuarter to 30 Jun 2023: revenue $108K, net income -$11.2MQuarter to 30 Jun 2023: revenue $108K, net income -$11.2MQuarter to 30 Sep 2023: revenue $141K, net income -$9.7MQuarter to 30 Sep 2023: revenue $141K, net income -$9.7MQuarter to 31 Dec 2023: revenue $156K, net income -$9.3MQuarter to 31 Dec 2023: revenue $156K, net income -$9.3MQuarter to 31 Mar 2024: revenue $205K, net income -$10.0MQuarter to 31 Mar 2024: revenue $205K, net income -$10.0MQuarter to 30 Jun 2024: revenue $163K, net income -$11.8MQuarter to 30 Jun 2024: revenue $163K, net income -$11.8MQuarter to 30 Sep 2024: revenue $165K, net income -$11.9MQuarter to 30 Sep 2024: revenue $165K, net income -$11.9MQuarter to 31 Dec 2024: revenue $151K, net income -$11.8MQuarter to 31 Dec 2024: revenue $151K, net income -$11.8MQuarter to 31 Mar 2025: revenue $109K, net income -$13.4MQuarter to 31 Mar 2025: revenue $109K, net income -$13.4MQuarter to 30 Jun 2025: revenue $121K, net income -$13.9MQuarter to 30 Jun 2025: revenue $121K, net income -$13.9MQuarter to 30 Sep 2025: revenue $120K, net income -$11.3MQuarter to 30 Sep 2025: revenue $120K, net income -$11.3MQuarter to 31 Dec 2025: revenue $243K, net income -$7.2MQuarter to 31 Dec 2025: revenue $243K, net income -$7.2MQuarter to 31 Mar 2026: revenue $41K, net income -$12.3MQuarter to 31 Mar 2026: revenue $41K, net income -$12.3MQuarter to 30 Jun 2026: revenue $104K, net income -$9.2MQuarter to 30 Jun 2026: revenue $104K, net income -$9.2MQuarter to 30 Sep 2026: revenue $171K, net income -$8.9MQuarter to 30 Sep 2026: revenue $171K, net income -$8.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $13.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$171K-$8.9M
30 Jun 2026$104K-$9.2M
31 Mar 2026$41K-$12.3M
31 Dec 2025$243K-$7.2M
30 Sep 2025$120K-$11.3M
30 Jun 2025$121K-$13.9M
31 Mar 2025$109K-$13.4M
31 Dec 2024$151K-$11.8M
30 Sep 2024$165K-$11.9M
30 Jun 2024$163K-$11.8M
31 Mar 2024$205K-$10.0M
31 Dec 2023$156K-$9.3M
30 Sep 2023$141K-$9.7M
30 Jun 2023$108K-$11.2M
31 Mar 2023$83K-$11.2M
31 Dec 2022$128K-$8.7M
30 Sep 2022$93K-$8.6M
30 Jun 2022$91K-$10.4M
31 Mar 2022$74K-$11.0M
31 Dec 2021$133K-$9.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $559K $501K
Revenue growthRevenue of the last 12 months compared with the 12 months before. +12% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$37.6M -$50.4M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.55 -$0.79
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -97.9% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $33.8M $60.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$33.8M (net cash) -$60.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.36
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 119 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 58.2 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.4 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Cardiff OncologyCRDF (this company) $66.3Mloss119+12%–
Tenaya TherapeuticsTNYA $65.3Mloss–––
Atara BiotherapeuticsATRA $64.5Mloss16.3-97%-369%
Neumora TherapeuticsNMRA $63.0Mloss–––
Champions OncologyCSBR $60.4Mloss1.00+6.7%-1.8%
Black Diamond TherapeuticsBDTX $75.3Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-25%

77 13F filers vs 103

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

23%

18.2M shares held by 13F filers (30 Sep 2026) of 77.8M outstanding (3 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

16%

12.3M shares sold short (30 Oct 2026) of 77.8M outstanding (3 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

30.8

12.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.2%

12.1M shares sold short in the report before, 12.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

43%

43% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

8 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $0.85 on 20 Nov 2026, -56% over 12 months (12-month range $0.73 to $3.21)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $1.1M in the last 12 months (the 12 months before: $1.7M).
Revenue per quarter. Revenue $171K in the latest quarter, +43% on a year earlier.
Capital spending per quarter. Capital spending $4K in the latest quarter, -78% on a year earlier.
Institutional holders (13F filers). 77 13F filers reported holding it in the latest 13F quarter, -26% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
27 Oct 20268-K and other filingsDirector or officer change
27 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Apr 20268-K and other filingsDirector or officer change
2 Apr 20268-K and other filingsDirector or officer change
24 Feb 20268-K and other filingsCompleted an acquisition or asset sale
27 Jan 20268-K and other filingsDirector or officer change
27 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Jun 20258-K and other filingsDirector or officer change
17 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Feb 2025Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 6.50 (2024-12-31); 6.2x the same period a year earlier
19 Dec 2024Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 1.0M)
27 Aug 2024Sharp changeShort interest spike: short interest spike, 6.7M vs usual 1.6M (2024-08-15); 10.1x the same period a year earlier
20 Aug 2024Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 5 (2024-06-30); 8.3x the same period a year earlier
28 May 2024Sharp changeShort interest spike: short interest spike, 4.6M vs usual 1.2M (2024-05-15); 8.5x the same period a year earlier
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 27 vs usual 5 (2024-03-31); 6.8x the same period a year earlier
14 May 2024Sharp changeShort interest spike: short interest spike, 4.4M vs usual 1.2M (2024-04-30); 7.2x the same period a year earlier
30 Apr 2024Sharp changeShort interest spike: short interest spike, 4.0M vs usual 1.1M (2024-04-15); 6.3x the same period a year earlier
16 Apr 2024Sharp changeShort interest spike: short interest spike, 3.4M vs usual 908K (2024-03-28); 5.5x the same period a year earlier
2 Apr 2024Sharp changeShort interest spike: short interest spike, 2.8M vs usual 673K (2024-03-15); 4.2x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 1.4M vs usual 673K (2023-11-30); 1.2x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 1.6M vs usual 673K (2023-11-15); 1.3x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 1.6M vs usual 673K (2023-10-31); 1.2x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 1.5M vs usual 673K (2023-10-13); 0.9x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 2.0M vs usual 673K (2023-09-29); 1.1x the same period a year earlier
2 Feb 20238-K and other filingsDirector or officer change
2 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Sep 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 320K)
12 Apr 20228-K and other filingsDirector or officer change
12 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Sep 2022: $345K published
Month from 1 Oct 2022: $20K published
Month from 1 Nov 2022: $14K published
Month from 1 Nov 2023: $22K published
Month from 1 Dec 2023: $41K published
Month from 1 Dec 2024: $1.0M published
Month from 1 Aug 2025: $710K published
Month from 1 Jun 2026: $66K published
Month from 1 Jul 2026: $1.1M published
Revenue per quarter
Quarter ended 31 Dec 2021: $133K; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $74K, +2.8% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $91K, +34% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $93K, +8.1% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $128K, -3.8% on a year earlier; public on 3 Mar 2023
Quarter ended 31 Mar 2023: $83K, +12% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $108K, +19% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $141K, +52% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $156K, +22% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $205K, +147% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $163K, +51% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $165K, +17% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $151K, -3.2% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $109K, -47% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $121K, -26% on a year earlier; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $120K, -27% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $243K, +61% on a year earlier; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $41K, -62% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $104K, -14% on a year earlier; public on 12 Aug 2026
Quarter ended 30 Sep 2026: $171K, +43% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2021: $0; public on 6 May 2022
Quarter ended 31 Dec 2021: $107K, +84% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $171K; public on 6 May 2022
Quarter ended 30 Jun 2022: $312K; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $448K, +357% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $75K, -30% on a year earlier; public on 3 Mar 2023
Quarter ended 31 Mar 2023: $8K, -95% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $251K, -20% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $315K, -30% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Mar 2024: $80K, +900% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 28 Feb 2025
Quarter ended 30 Sep 2025: $18K; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 25 Feb 2026
Quarter ended 30 Sep 2026: $4K, -78% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 82; public on 14 Feb 2022
31 Mar 2022 report: 88; public on 16 May 2022
30 Jun 2022 report: 65; public on 15 Aug 2022
30 Sep 2022 report: 54; public on 14 Nov 2022
31 Dec 2022 report: 56; public on 14 Feb 2023
31 Mar 2023 report: 53; public on 15 May 2023
30 Jun 2023 report: 51; public on 14 Aug 2023
30 Sep 2023 report: 50; public on 14 Nov 2023
31 Dec 2023 report: 51; public on 14 Feb 2024
31 Mar 2024 report: 74; public on 15 May 2024
30 Jun 2024 report: 80; public on 14 Aug 2024
30 Sep 2024 report: 78; public on 14 Nov 2024
31 Dec 2024 report: 112; public on 14 Feb 2025
31 Mar 2025 report: 112; public on 15 May 2025
30 Jun 2025 report: 108; public on 14 Aug 2025
30 Sep 2025 report: 104; public on 14 Nov 2025
31 Dec 2025 report: 106; public on 17 Feb 2026
31 Mar 2026 report: 111; public on 15 May 2026
30 Jun 2026 report: 103; public on 14 Aug 2026
30 Sep 2026 report: 77; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $1.1M (16 Jul 2026), 27× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $1.1M in the last 12 months (the 12 months before: $1.7M).
  • Revenue per quarter: Revenue $171K in the latest quarter, +43% on a year earlier.
  • Capital spending per quarter: Capital spending $4K in the latest quarter, -78% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 49 insider trades

No trades in the last 90 days; the latest was filed 16 Jul 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
16 Jul 2026Gary W PaceDirectorBuy687,285$1.46$1.0MForm 4
16 Jul 2026Mani MohindruChief Executive OfficerBuy34,364$1.46$50KForm 4
22 Jun 2026Mani MohindruChief Executive OfficerBuy24,703$1.21$30KForm 4
22 Jun 2026Gary W PaceDirectorBuy30,000$1.22$37KForm 4
31 Jul 2025Gary W PaceDirectorBuy290,000$2.45$710KForm 4
18 Dec 2024James E. LevineChief Financial OfficerBuy7,716$4.76$37KForm 4
16 Dec 2024Renee P TannenbaumDirectorBuy10,000$3.42$34KForm 4
12 Dec 2024Gary W PaceDirectorBuy361,615$2.60$940KForm 4

77 institutions reported shares at the end of Q3 2026, 23% of the shares outstanding; 2 opened a position, 26 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Laurion Capital Management LP3.1M3.98%$3.7MNo change
Vanguard Capital Management LLC2.9M3.69%$3.5M-28K-1.0%
Pfizer Inc2.4M3.10%$3.0MNo change
Franklin Templeton Inc1.2M1.55%$1.0MNo change
BlackRock, Inc.936K1.20%$1.1M-37K-3.8%
Blair William & Co917K1.18%$1.1M+4,462+0.5%
Geode Capital Management, LLC840K1.08%$1.0M+20K+2.4%
GoalVest Advisory LLC687K0.88%$832KNew+687K
Gsa Capital Partners LLP538K0.69%+364K+210%
Vanguard Fiduciary Trust Co477K0.61%$577K+66K+16%

Company events

All 68 company events

In 12 months: 4 director or officer changes, 4 major agreements, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
27 Oct 2026Director or officer changeSame filing: changed its bylaws or fiscal year8-K
14 Sep 2026Signed a major agreement8-K
16 Jul 2026Signed a major agreement8-K
29 May 2026Signed a major agreement8-K
9 Apr 2026Director or officer change8-K
2 Apr 2026Director or officer change; Signed a major agreement8-K
24 Feb 2026Completed an acquisition or asset sale8-K
27 Jan 2026Director or officer change8-K

The 5 newest of 63 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

27 Aug 2024confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Cardiff Oncology (CRDF): saw 25 13F filers open a new position in the quarter ended 30 Jun 2024, 8.3× the same quarter last year, while it had 6.7M shares sold short in the 15 Aug 2024 report, 10× the same report last year. Two unrelated kinds of activity within 7 days.

  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2024
  • Short interest and volume: Short interest spike, became public on 27 Aug 2024
2022-06-30: 82022-09-30: 42022-12-31: 102023-03-31: 42023-06-30: 32023-09-30: 62023-12-31: 42024-03-31: 272024-06-30: 25
The quarter ended 30 Jun 2024 against the 8 quarters before it. this quarterearliernormal: 5
See the evidence (2 changes)

Institutional holdings: Many funds opening a new position became public on 14 Aug 2024

Cardiff Oncology saw 25 13F filers open a new position in the quarter ended 30 Jun 2024, 8.3× the same quarter last year.

This period
25 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+6.7
Same quarter last year
3
History used
1,461 days
2022-06-30: 82022-09-30: 42022-12-31: 102023-03-31: 42023-06-30: 32023-09-30: 62023-12-31: 42024-03-31: 272024-06-30: 25
the quarter ended 30 Jun 20248 earlier quartersnormal: 5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 27 Aug 2024

Cardiff Oncology had 6.7M shares sold short in the 15 Aug 2024 report, 10× the same report last year.

This period
6.7M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
1.6M
Typical spread (median absolute deviation)
941K
How far from its usual level
+3.7
Same report last year
666K
History used
1,553 days
2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M2024-04-30: 4.4M2024-05-15: 4.6M2024-05-31: 4.5M2024-06-14: 4.0M2024-06-28: 4.2M2024-07-15: 5.1M2024-07-31: 5.8M2024-08-15: 6.7M
the 15 Aug 2024 report24 earlier reportsnormal: 1.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

21 May 2024confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Cardiff Oncology (CRDF): had 4.4M shares sold short in the 30 Apr 2024 report, 7.2× the same report last year, while it saw 27 13F filers open a new position in the quarter ended 31 Mar 2024, 6.8× the same quarter last year. Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 25 Apr 2024
  • Short interest and volume: Short interest spike, became public on 10 May 2024
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2024
  • Short interest and volume: Short interest spike, became public on 25 May 2024
2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M2024-04-30: 4.4M
The 30 Apr 2024 report against the 24 reports before it. this reportearliernormal: 1.2M
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 25 Apr 2024

Cardiff Oncology had 4.0M shares sold short in the 15 Apr 2024 report, 6.3× the same report last year.

This period
4.0M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
1.1M
Typical spread (median absolute deviation)
500K
How far from its usual level
+3.8
Same report last year
632K
History used
1,431 days
2023-04-14: 632K2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M
the 15 Apr 2024 report24 earlier reportsnormal: 1.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 May 2024

Cardiff Oncology had 4.4M shares sold short in the 30 Apr 2024 report, 7.2× the same report last year.

This period
4.4M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
530K
How far from its usual level
+4.1
Same report last year
617K
History used
1,446 days
2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M2024-04-30: 4.4M
the 30 Apr 2024 report24 earlier reportsnormal: 1.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2024

Cardiff Oncology saw 27 13F filers open a new position in the quarter ended 31 Mar 2024, 6.8× the same quarter last year.

This period
27 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+7.3
Same quarter last year
4
History used
1,370 days
2022-03-31: 132022-06-30: 82022-09-30: 42022-12-31: 102023-03-31: 42023-06-30: 32023-09-30: 62023-12-31: 42024-03-31: 27
the quarter ended 31 Mar 20248 earlier quartersnormal: 5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 25 May 2024

Cardiff Oncology had 4.6M shares sold short in the 15 May 2024 report, 8.5× the same report last year.

This period
4.6M (the 15 May 2024 report)
Normal report (median of 24 earlier)
1.2M
Typical spread (median absolute deviation)
635K
How far from its usual level
+3.6
Same report last year
542K
History used
1,461 days
2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M2024-04-30: 4.4M2024-05-15: 4.6M
the 15 May 2024 report24 earlier reportsnormal: 1.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 27 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 27 Oct 2026Filings record

    Director or officer change

  3. 17 Jul 2026Insiders record

    PACE GARY W (director) bought 687,285 shares of CRDF ($1.0M) (dated 16 Jul 2026)

  4. 17 Jul 2026Insiders record

    Mohindru Mani (Chief Executive Officer) bought 34,364 shares of CRDF ($50,171) (dated 16 Jul 2026)

  5. 23 Jun 2026Insiders record

    Mohindru Mani (Chief Executive Officer) bought 24,703 shares of CRDF ($29,891) (dated 22 Jun 2026)

  6. 23 Jun 2026Insiders record

    PACE GARY W (director) bought 30,000 shares of CRDF ($36,600) (dated 22 Jun 2026)

  7. 9 Apr 2026Filings record

    Director or officer change

  8. 2 Apr 2026Filings record

    Director or officer change

  9. 24 Feb 2026Filings record

    Completed an acquisition or asset sale

  10. 27 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 27 Jan 2026Filings record

    Director or officer change

  12. 1 Aug 2025Insiders record

    PACE GARY W (director) bought 290,000 shares of CRDF ($710,500) (dated 31 Jul 2025)

  13. 17 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 17 Jun 2025Filings record

    Director or officer change

  15. 14 Feb 2025Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 31 Dec 2024, 6.2× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 6.5.

    See the evidence
    This period
    25 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    6.5
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +4.2
    Same quarter last year
    4
    History used
    1,645 days
    2022-12-31: 102023-03-31: 42023-06-30: 32023-09-30: 62023-12-31: 42024-03-31: 272024-06-30: 252024-09-30: 72024-12-31: 25
    the quarter ended 31 Dec 20248 earlier quartersnormal: 6.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  16. 19 Dec 2024Insiders change

    had 3 insiders buy $1.0M of its shares on the open market within 30 days (3 filings).

    Who bought: Pace Gary W, Tannenbaum Renee P, Levine James E..

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $1.0M
    Window
    19 Nov 2024 to 19 Dec 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  17. 19 Dec 2024Insiders record

    Levine James E. (Chief Financial Officer) bought 7,716 shares of CRDF ($36,736) (dated 18 Dec 2024)

  18. 17 Dec 2024Insiders record

    TANNENBAUM RENEE P (director) bought 10,000 shares of CRDF ($34,200) (dated 16 Dec 2024)

  19. 13 Dec 2024Insiders record

    PACE GARY W (director) bought 361,615 shares of CRDF ($940,199) (dated 12 Dec 2024)

  20. 27 Aug 2024several at once

    saw 25 13F filers open a new position in the quarter ended 30 Jun 2024, 8.3× the same quarter last year, while it had 6.7M shares sold short in the 15 Aug 2024 report, 10× the same report last year. Two unrelated kinds of activity within 7 days.

    See the evidence (2 changes)

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2024

    Cardiff Oncology saw 25 13F filers open a new position in the quarter ended 30 Jun 2024, 8.3× the same quarter last year.

    This period
    25 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +6.7
    Same quarter last year
    3
    History used
    1,461 days
    2022-06-30: 82022-09-30: 42022-12-31: 102023-03-31: 42023-06-30: 32023-09-30: 62023-12-31: 42024-03-31: 272024-06-30: 25
    the quarter ended 30 Jun 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 27 Aug 2024

    Cardiff Oncology had 6.7M shares sold short in the 15 Aug 2024 report, 10× the same report last year.

    This period
    6.7M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    941K
    How far from its usual level
    +3.7
    Same report last year
    666K
    History used
    1,553 days
    2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M2024-04-30: 4.4M2024-05-15: 4.6M2024-05-31: 4.5M2024-06-14: 4.0M2024-06-28: 4.2M2024-07-15: 5.1M2024-07-31: 5.8M2024-08-15: 6.7M
    the 15 Aug 2024 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  21. 27 Aug 2024Short interest and volume change

    had 6.7M shares sold short in the 15 Aug 2024 report, 10× the same report last year.

    Same report last year: 666K; its normal report is 1.6M.

    See the evidence
    This period
    6.7M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    1.6M
    Typical spread (median absolute deviation)
    941K
    How far from its usual level
    +3.7
    Same report last year
    666K
    History used
    1,553 days
    2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M2024-04-30: 4.4M2024-05-15: 4.6M2024-05-31: 4.5M2024-06-14: 4.0M2024-06-28: 4.2M2024-07-15: 5.1M2024-07-31: 5.8M2024-08-15: 6.7M
    the 15 Aug 2024 report24 earlier reportsnormal: 1.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 14 Aug 2024Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 30 Jun 2024, 8.3× the same quarter last year.

    Same quarter last year: 3; its normal quarter is 5.

    See the evidence
    This period
    25 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +6.7
    Same quarter last year
    3
    History used
    1,461 days
    2022-06-30: 82022-09-30: 42022-12-31: 102023-03-31: 42023-06-30: 32023-09-30: 62023-12-31: 42024-03-31: 272024-06-30: 25
    the quarter ended 30 Jun 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  23. 25 May 2024Short interest and volume change

    had 4.6M shares sold short in the 15 May 2024 report, 8.5× the same report last year.

    Same report last year: 542K; its normal report is 1.2M.

    See the evidence
    This period
    4.6M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    635K
    How far from its usual level
    +3.6
    Same report last year
    542K
    History used
    1,461 days
    2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M2024-04-30: 4.4M2024-05-15: 4.6M
    the 15 May 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 21 May 2024several at once

    had 4.4M shares sold short in the 30 Apr 2024 report, 7.2× the same report last year, while it saw 27 13F filers open a new position in the quarter ended 31 Mar 2024, 6.8× the same quarter last year. Two unrelated kinds of activity within 28 days.

    See the evidence (4 changes)

    Short interest and volume: Short interest spike became public on 25 Apr 2024

    Cardiff Oncology had 4.0M shares sold short in the 15 Apr 2024 report, 6.3× the same report last year.

    This period
    4.0M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    500K
    How far from its usual level
    +3.8
    Same report last year
    632K
    History used
    1,431 days
    2023-04-14: 632K2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M
    the 15 Apr 2024 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 May 2024

    Cardiff Oncology had 4.4M shares sold short in the 30 Apr 2024 report, 7.2× the same report last year.

    This period
    4.4M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    530K
    How far from its usual level
    +4.1
    Same report last year
    617K
    History used
    1,446 days
    2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M2024-04-30: 4.4M
    the 30 Apr 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 15 May 2024

    Cardiff Oncology saw 27 13F filers open a new position in the quarter ended 31 Mar 2024, 6.8× the same quarter last year.

    This period
    27 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +7.3
    Same quarter last year
    4
    History used
    1,370 days
    2022-03-31: 132022-06-30: 82022-09-30: 42022-12-31: 102023-03-31: 42023-06-30: 32023-09-30: 62023-12-31: 42024-03-31: 27
    the quarter ended 31 Mar 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 25 May 2024

    Cardiff Oncology had 4.6M shares sold short in the 15 May 2024 report, 8.5× the same report last year.

    This period
    4.6M (the 15 May 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    635K
    How far from its usual level
    +3.6
    Same report last year
    542K
    History used
    1,461 days
    2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M2024-04-30: 4.4M2024-05-15: 4.6M
    the 15 May 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  25. 15 May 2024Institutional holdings change

    saw 27 13F filers open a new position in the quarter ended 31 Mar 2024, 6.8× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 5.

    See the evidence
    This period
    27 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +7.3
    Same quarter last year
    4
    History used
    1,370 days
    2022-03-31: 132022-06-30: 82022-09-30: 42022-12-31: 102023-03-31: 42023-06-30: 32023-09-30: 62023-12-31: 42024-03-31: 27
    the quarter ended 31 Mar 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  26. 10 May 2024Short interest and volume change

    had 4.4M shares sold short in the 30 Apr 2024 report, 7.2× the same report last year.

    Same report last year: 617K; its normal report is 1.2M.

    See the evidence
    This period
    4.4M (the 30 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    530K
    How far from its usual level
    +4.1
    Same report last year
    617K
    History used
    1,446 days
    2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M2024-04-30: 4.4M
    the 30 Apr 2024 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 25 Apr 2024Short interest and volume change

    had 4.0M shares sold short in the 15 Apr 2024 report, 6.3× the same report last year.

    Same report last year: 632K; its normal report is 1.1M.

    See the evidence
    This period
    4.0M (the 15 Apr 2024 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    500K
    How far from its usual level
    +3.8
    Same report last year
    632K
    History used
    1,431 days
    2023-04-14: 632K2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M2024-04-15: 4.0M
    the 15 Apr 2024 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 10 Apr 2024Short interest and volume change

    had 3.4M shares sold short in the 28 Mar 2024 report, 5.5× the same report last year.

    Same report last year: 624K; its normal report is 908K.

    See the evidence
    This period
    3.4M (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    908K
    Typical spread (median absolute deviation)
    374K
    How far from its usual level
    +4.5
    Same report last year
    624K
    History used
    1,413 days
    2023-03-31: 624K2023-04-14: 632K2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M2024-03-28: 3.4M
    the 28 Mar 2024 report24 earlier reportsnormal: 908K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 27 Mar 2024Short interest and volume change

    had 2.8M shares sold short in the 15 Mar 2024 report, 4.2× the same report last year.

    Same report last year: 674K; its normal report is 673K.

    See the evidence
    This period
    2.8M (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    673K
    Typical spread (median absolute deviation)
    168K
    How far from its usual level
    +8.6
    Same report last year
    674K
    History used
    1,400 days
    2023-03-15: 674K2023-03-31: 624K2023-04-14: 632K2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M2023-12-15: 1.4M2023-12-29: 1.3M2024-01-12: 1.1M2024-01-31: 1.3M2024-02-15: 1.2M2024-02-29: 1.2M2024-03-15: 2.8M
    the 15 Mar 2024 report24 earlier reportsnormal: 673K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 20 Dec 2023Insiders record

    PACE GARY W (director) bought 30,000 shares of CRDF ($41,100) (dated 19 Dec 2023)

  31. 12 Dec 2023Short interest and volume change

    had 1.4M shares sold short in the 30 Nov 2023 report, 1.2× the same report last year.

    Same report last year: 1.2M; its normal report is 673K.

    See the evidence
    This period
    1.4M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    673K
    Typical spread (median absolute deviation)
    139K
    How far from its usual level
    +3.7
    Same report last year
    1.2M
    History used
    1,294 days
    2022-11-30: 1.2M2022-12-15: 1.1M2022-12-30: 1.1M2023-01-13: 1.0M2023-01-31: 906K2023-02-15: 801K2023-02-28: 684K2023-03-15: 674K2023-03-31: 624K2023-04-14: 632K2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M2023-11-30: 1.4M
    the 30 Nov 2023 report24 earlier reportsnormal: 673K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 28 Nov 2023Short interest and volume change

    had 1.6M shares sold short in the 15 Nov 2023 report, 1.3× the same report last year.

    Same report last year: 1.2M; its normal report is 673K.

    See the evidence
    This period
    1.6M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    673K
    Typical spread (median absolute deviation)
    139K
    How far from its usual level
    +4.5
    Same report last year
    1.2M
    History used
    1,279 days
    2022-11-15: 1.2M2022-11-30: 1.2M2022-12-15: 1.1M2022-12-30: 1.1M2023-01-13: 1.0M2023-01-31: 906K2023-02-15: 801K2023-02-28: 684K2023-03-15: 674K2023-03-31: 624K2023-04-14: 632K2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M2023-11-15: 1.6M
    the 15 Nov 2023 report24 earlier reportsnormal: 673K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 15 Nov 2023Insiders record

    PACE GARY W (director) bought 22,950 shares of CRDF ($22,491) (dated 14 Nov 2023)

  34. 10 Nov 2023Short interest and volume change

    had 1.6M shares sold short in the 31 Oct 2023 report, 1.2× the same report last year.

    Same report last year: 1.3M; its normal report is 673K.

    See the evidence
    This period
    1.6M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    673K
    Typical spread (median absolute deviation)
    139K
    How far from its usual level
    +4.6
    Same report last year
    1.3M
    History used
    1,264 days
    2022-10-31: 1.3M2022-11-15: 1.2M2022-11-30: 1.2M2022-12-15: 1.1M2022-12-30: 1.1M2023-01-13: 1.0M2023-01-31: 906K2023-02-15: 801K2023-02-28: 684K2023-03-15: 674K2023-03-31: 624K2023-04-14: 632K2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M2023-10-31: 1.6M
    the 31 Oct 2023 report24 earlier reportsnormal: 673K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 25 Oct 2023Short interest and volume change

    had 1.5M shares sold short in the 13 Oct 2023 report, 5.9% below the same report last year.

    Same report last year: 1.6M; its normal report is 673K.

    See the evidence
    This period
    1.5M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    673K
    Typical spread (median absolute deviation)
    139K
    How far from its usual level
    +4.1
    Same report last year
    1.6M
    History used
    1,246 days
    2022-10-14: 1.6M2022-10-31: 1.3M2022-11-15: 1.2M2022-11-30: 1.2M2022-12-15: 1.1M2022-12-30: 1.1M2023-01-13: 1.0M2023-01-31: 906K2023-02-15: 801K2023-02-28: 684K2023-03-15: 674K2023-03-31: 624K2023-04-14: 632K2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M2023-10-13: 1.5M
    the 13 Oct 2023 report24 earlier reportsnormal: 673K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 12 Oct 2023Short interest and volume change

    had 2.0M shares sold short in the 29 Sep 2023 report, 1.1× the same report last year.

    Same report last year: 1.8M; its normal report is 673K.

    See the evidence
    This period
    2.0M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    673K
    Typical spread (median absolute deviation)
    139K
    How far from its usual level
    +6.6
    Same report last year
    1.8M
    History used
    1,232 days
    2022-09-30: 1.8M2022-10-14: 1.6M2022-10-31: 1.3M2022-11-15: 1.2M2022-11-30: 1.2M2022-12-15: 1.1M2022-12-30: 1.1M2023-01-13: 1.0M2023-01-31: 906K2023-02-15: 801K2023-02-28: 684K2023-03-15: 674K2023-03-31: 624K2023-04-14: 632K2023-04-28: 617K2023-05-15: 542K2023-05-31: 541K2023-06-15: 532K2023-06-30: 537K2023-07-14: 493K2023-07-31: 518K2023-08-15: 666K2023-08-31: 536K2023-09-15: 673K2023-09-29: 2.0M
    the 29 Sep 2023 report24 earlier reportsnormal: 673K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 2 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 2 Feb 2023Filings record

    Director or officer change

  39. 30 Nov 2022Insiders record

    Erlander Mark (Chief Executive Officer) bought 10,000 shares of CRDF ($14,300) (dated 29 Nov 2022)

  40. 12 Oct 2022Insiders record

    Armitage James O (director) bought 13,000 shares of CRDF ($20,280) (dated 11 Oct 2022)

Showing the newest 40 of 123 entries; narrow the window or the kind of data to see older ones.

Not listed: 307 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001213037
Ticker
CRDF
Domain
cardiffoncology.com
Hq location
CA|SAN DIEGO|92121 (1 unverified)
Name
Cardiff Oncology, Inc., Trovagene, Inc., USED KAR PARTS INC, XENOMICS INC
  • SEC Form 13F institutional holdings234 data points30 Jun 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)352 records7 Jan 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)985 data points3 Aug 1999 to 3 Nov 2026
  • SEC Form 4 insider transactions49 records, 124 data points15 Nov 2016 to 16 Jul 2026
  • FINRA short interest (twice monthly)465 data points15 May 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3288 data points8 May 2020 to 20 Nov 2026